Microbial derived immunotherapeutic products
Total Trials
11
As Lead Sponsor
4
As Collaborator
7
Total Enrollment
2,111
NCT03647995
Probiotics in the Prevention of Antibiotic Induced Diarrhea and Clostridium Difficile Associated Diarrhea.
Phase: N/A
Role: Collaborator
Start: Sep 1, 2018
Completion: Feb 2, 2019
NCT04186247
Personalized AZithromycin/metronidAZole Therapy in Pediatric Crohn's Disease (CD)
Phase: Phase 2
Start: Aug 13, 2021
Completion: Dec 31, 2023
NCT05222516
Immunomodulation by OM-85 (Broncho-Vaxom) in Early AD
Role: Lead Sponsor
Start: Dec 20, 2021
Completion: Jul 13, 2023
NCT05305508
Assessment of the Efficacy of Calcium Dobesilate vs. Placebo on SARS-CoV-2 Viral Load Amongst Outpatients With COVID-19.
Start: May 17, 2022
Completion: Feb 5, 2024
NCT05533892
Nocardia Rubra Cell Wall Skeleton (N-CWS) Plus HAIC, Lenvatinib and Tislelizumab in Treating Patients With Advanced HCC
Phase: Phase 1
Start: Sep 1, 2022
Completion: Feb 28, 2025
NCT05677763
OM-85 in Paediatric Recurrent Respiratory Tract Infections With Wheezing Lower Respiratory Illness
Phase: Phase 4
Start: Dec 12, 2022
Completion: Sep 28, 2026
NCT05857930
A Study to Assess the Efficacy and Safety of Daily OM-85 in Young Children With Recurrent Wheezing
Start: Jun 20, 2023
Completion: Sep 30, 2026
NCT06345014
The Efficacy and Safety of OM-89 in Patients With Recurrent Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Start: Dec 20, 2023
Completion: Mar 30, 2026
NCT06486662
A Clinical Study Investigating OM-85-IN Safety and Tolerability in Healthy Volunteers and Mild Allergic Asthma Patients
Start: Jun 14, 2024
Completion: Feb 19, 2025
NCT07178002
OM 85 to Prevent Respiratory Infections in Older At Risk Patients
Start: Dec 19, 2024
Completion: Apr 30, 2026
NCT06655272
Start: Feb 1, 2025
Loading map...